Drugs / AL0704rP
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00671268 | Mar 2008 → Mar 2012 | nasal cavity disorder | Allergopharma GmbH & Co. KG | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AL0704rP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00671268 ↗ |
| Modality | Protein / enzyme biologic | “high-dosed subcutaneous recombinant preparation” NCT00671268 ↗ |
| Route | Subcutaneous | “strict subcutaneous” NCT00671268 ↗ |